Get the Stockscreener App
12.52
27.49%
2.70
After Hours:
13.00
0.48
+3.83%
Conexeu Sciences Inc stock is traded at $12.52, with a volume of 122.24K.
It is up +27.49% in the last 24 hours and up +0.00% over the past month.
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
See More
Previous Close:
$9.82
Open:
$9.98
24h Volume:
122.24K
Relative Volume:
5.42
Market Cap:
$335.01M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.19%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.60
$13.82
1-Week Range:
$9.60
$13.89
52-Week Range:
$9.60
$18.79
Conexeu Sciences Inc Stock (CNXU) Company Profile
Compare CNXU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNXU
Conexeu Sciences Inc
|
12.52 | 262.77M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Conexeu Sciences Inc Stock (CNXU) Latest News
Conexeu builds board as regenerative tissue ambitions widen - The Pharma Letter
Conexeu Sciences Inc. 2026 Q2 10-Q Report: Financials, Risks, and Company Overview - Minichart
Conexeu Sciences Inc. 3Q 2026: Revenue $0 Net loss $2.3M, EPS $(0.11) — 10-Q Summary - TradingView
CNXU: Board expanded to nine, with updated director compensation and new CCO agreement featuring equity awards - TradingView
Conexeu Sciences expands board, names chief commercial officer By Investing.com - Investing.com South Africa
Conexeu Sciences expands board, names chief commercial officer - Investing.com
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing - The Manila Times
Conexeu Sciences (CNXU) 10K Form and Latest SEC Filings 2026 - MarketBeat
Top Conexeu Sciences (CNXU) Competitors 2026 - MarketBeat
Conexeu Sciences Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Conexeu Sciences Inc. Rings the Closing Bell - Nasdaq
MC_061026_tower-shot.jpg - Nasdaq
A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus - GlobeNewswire
Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program - The National Law Review
Conexeu Sciences Inc. Reports Manufacturing Scale Up And Regulatory Progress For Lead CXU Wound Care Program - marketscreener.com
Conexeu Sciences stock gains on wound care device progress By Investing.com - Investing.com South Africa
Conexeu Sciences stock gains on wound care device progress - Investing.com
Conexeu Sciences provides update on manufacturing scale up for wound care device - TipRanks
Conexeu advances manufacturing for wound care device ahead of 2027 FDA filing - Investing.com
Flowable gel for complex wounds readied for 2027 FDA 510(k) bid - Stock Titan
The Body as Blueprint - lifehealth.com
Top SkyAI, Inc. Warrant (SKYAW) Competitors 2026 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
2026 Special Olympics USA Games Rings the Nasdaq Stock Market Closing Bell - Nasdaq
CNXU Technical Analysis | Trend, Signals & Chart Patterns | CONEXEU SCIENCES INC (NASDAQ:CNXU) - ChartMill
Before the IPO: 4 Companies That Rewarded Investors Who Got In Early - Investing.com
Before the IPO: 4 Companies That Rewarded Investors Who Got In Early - sharewise.com
Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026 - The Manila Times
Top Inspira Technologies OXY B.H.N. (QTEX) Competitors 2026 - MarketBeat
Conexeu Sciences (CNXU) Stock Price, News & Analysis - MarketBeat
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts - marketscreener.com
How Investors Are Reacting To Conexeu Sciences (CNXU) 3D-Printed Bioregenerative Breast Matrix Initiative - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch - RTTNews
Assessing Conexeu Sciences (CNXU) Valuation After Launch Of Preclinical B.R.E.A.S.T. Program - simplywall.st
CNXU Price History for Conexeu Sciences Stock - Barchart.com
Conexeu Sciences (CNXU) Stock Trends and Sentiment 2026 - MarketBeat
Conexeu Sciences Inc. (CNXU) Competitors - Meyka
Conexeu Debuts on Nasdaq With Preclinical Regenerative Tissue Platform - 3D Printing Industry
Regenerative Breast Matrix Platforms - Trend Hunter
Conexeu Sciences (CNXU) Stock Chart and Price History 2026 - MarketBeat
Conexeu Sciences launches preclinical program for bioregenerative breast matrix - BioWorld News
CNXU Stock Chart | CONEXEU SCIENCES INC (NASDAQ:CNXU) - ChartMill
Conexeu Sciences Inc Stock (CNXU) Financials Data
There is no financial data for Conexeu Sciences Inc (CNXU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Conexeu Sciences Inc Stock (CNXU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sharpe Jeffrey Nathan | Director |
May 22 '26 |
Option Exercise |
0.00 |
500,000 |
500 |
1,000,000 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):